Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut. Moreover, increased optimism spurs an uptick in M&A activity, contributing to a more active biotech sector. Hence, discarding underperforming biotech stocks to sell is imperative, as the industry is picking up steam again. Rallybio (RLYB) Source: Shu ...

This innovative biotechnology company hopes to turn things around. Once upon a time, Ginkgo Bioworks (DNA -0.25%) was viewed by many as a rising star in the biotechnology world. However, since its initial public offering in September 2021, the stock has plunged 95%. So far in 2024, Ginkgo's shares have fallen more than 60%. Can Ginkgo Bioworks stage a major comeback? Or is the stock likely to continue floundering? Two Motley Fool contributors make the bull and bear arguments for Ginkgo. Bull case: A growing ...

Its vision is ambitious, but can it actually be made to work? In the last three months, Ginkgo Bioworks' (DNA -10.27%) shares fell by 50%. To the enterprising investor, such a decline by the Boston-based biotech specialist isn't necessarily a sign of disaster, and in fact could well be a sign of an opportunity to buy shares at a discount -- assuming those shares can be reasonably expected to rise again in the future. Is that the case with this company, or would it be better to look for opportunities elsewhe ...

Venlo, the Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample. The QIAseq Multimodal DNA/RNA Lib Kit facilitates multiomics, the ...

You don't need to buy her picks, but it's worth understanding them. Cathie Wood's commitment to buying shares of businesses working on disruptive innovations, via her ARK Innovation ETF and ARK Genomic Revolution ETF, makes her investing style very much on the riskier side of the spectrum -- especially when she invests in already risky areas like biotech. But if her theses are correct, the upside to investors could be tremendous, assuming they can tolerate what might be a very long and bumpy ride between bu ...

It needs to work within the constraints imposed by these three issues. Thanks to its promises of low-cost bioengineering and biomanufacturing services, Ginkgo Bioworks (DNA 0.70%) could one day be the kind of biotech that everyone else in the biopharma sector wants to work with to advance their own products. Delivering on those plans would make it a smart stock to own as well. But for now, it's still trying to find its footing, and it's a riskier bet than investors may realize. So without further ado, here ...

Reasons to buy Ginkgo Bioworks The company's cell engineering platform combines robotics and artificial intelligence (AI) to produce new cell lines for its clients. This is important because many top-selling drugs are manufactured by genetically modified cells that produce a specific protein. Disrupting the biopharmaceutical manufacturing industry could be extremely lucrative and it isn't the only way Ginkgo's cell engineering platform can earn money. For example, it recently partnered with plant-biotech co ...

Is Ginkgo stock a sell? Although possessing enough cash to keep it going for about two years at its current burn rate, I'm just not sure this company is going anywhere fast. To me, that makes Ginkgo stock a sell. Ginkgo Bioworks has become a penny stock -- and that's the least of its problems, Massaro is most concerned with management commentary that new "cell programs" -- of which the company expects to add 100 this year -- are no longer a great forecaster of revenue growth, and may give investors a false ...

Can this struggling stock turn things around? Ginkgo Bioworks (DNA -3.98%) is a cell programming company that claims to have large addressable markets (for bioengineered products) in multiple industries in which it can play a key role, and that those are worth trillions of dollars in total. But the problem is it may take more than a decade for those markets to reach that kind of size. Investors could require a lot of patience. While there may be a lot of potential for the business in the long run, investors ...

A few enterprising businesses are marketing themselves differently. As you may have heard, there's a new trend in biotech lingo wherein companies call themselves "TechBio" rather than "biotech" to emphasize their forward-thinking about the role of information technology. Biotechs like Ginkgo Bioworks (DNA 2.63%), Recursion Pharmaceuticals (RXRX 6.01%), and Schrödinger (SDGR 0.30%) could easily be described by the term, and some, like Recursion, even describe themselves that way. But what does this new term ...